Bolt Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Bolt Biotherapeutics
BOLT Stock  USD 0.41  0.01  2.38%   
Bolt Biotherapeutics financial statements provide useful quarterly and yearly information to potential Bolt Biotherapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Bolt Biotherapeutics financial statements helps investors assess Bolt Biotherapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Bolt Biotherapeutics' valuation are summarized below:
Gross Profit
-52.3 M
Market Capitalization
15.7 M
Enterprise Value Revenue
270.646
Revenue
9.8 M
Earnings Share
(1.71)
There are currently one hundred twenty fundamental signals for Bolt Biotherapeutics that can be evaluated and compared over time across rivals. All traders should validate Bolt Biotherapeutics' prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 46.3 M in 2025. Enterprise Value is likely to drop to about 56.5 M in 2025

Bolt Biotherapeutics Total Revenue

9.51 Million

Check Bolt Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bolt Biotherapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 7.5 M, Interest Income of 7.5 M or Depreciation And Amortization of 2.5 M, as well as many indicators such as Price To Sales Ratio of 5.87, Dividend Yield of 0.0 or PTB Ratio of 0.35. Bolt financial statements analysis is a perfect complement when working with Bolt Biotherapeutics Valuation or Volatility modules.
  
Check out the analysis of Bolt Biotherapeutics Correlation against competitors.
For more information on how to buy Bolt Stock please use our How to Invest in Bolt Biotherapeutics guide.

Bolt Biotherapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets147.8 M183.8 M79.1 M
Slightly volatile
Short and Long Term Debt Total16.2 M23.3 M8 M
Slightly volatile
Other Current Liabilities8.2 M14.4 M5.1 M
Slightly volatile
Total Current Liabilities16.1 M23.5 M9.3 M
Slightly volatile
Other Liabilities15.7 M14.9 M4.7 M
Slightly volatile
Property Plant And Equipment Net20.6 M27.7 M10.8 M
Slightly volatile
Accounts Payable2.7 M3.4 M1.8 M
Slightly volatile
Cash13.5 M9.7 M14.6 M
Very volatile
Non Current Assets Total48.3 M62.2 M24.3 M
Slightly volatile
Non Currrent Assets Other2.4 M4.1 M1.4 M
Slightly volatile
Other Assets1.091.15932.8 K
Pretty Stable
Cash And Short Term Investments96.9 M117.5 M53.3 M
Slightly volatile
Common Stock Shares Outstanding35.4 M43.5 M21.7 M
Slightly volatile
Liabilities And Stockholders Equity147.8 M183.8 M79.1 M
Slightly volatile
Non Current Liabilities Total46.8 M23.9 M40.9 M
Pretty Stable
Capital Lease Obligations16.2 M23.3 M8 M
Slightly volatile
Other Current Assets2.6 M4 M1.5 M
Slightly volatile
Total Liabilities58.5 M42.3 M49.7 M
Slightly volatile
Property Plant And Equipment Gross21.7 M34.3 M11.6 M
Slightly volatile
Total Current Assets99.5 M121.6 M54.8 M
Slightly volatile
Non Current Liabilities Other36.8 K38.7 K1.9 M
Pretty Stable
Net Working Capital83.5 M98 M45.5 M
Slightly volatile
Short Term Debt3.4 M3.2 M1.6 M
Slightly volatile
Property Plant Equipment19.5 M32.8 M11.3 M
Slightly volatile
Current Deferred Revenue2 M2.5 M1.2 M
Slightly volatile
Net Receivables1.6 M1.5 M523.5 K
Slightly volatile
Deferred Long Term Liabilities1.9 M2.1 M2.3 M
Slightly volatile

Bolt Biotherapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income7.5 M7.1 M1.6 M
Slightly volatile
Interest Income7.5 M7.1 M1.6 M
Slightly volatile
Depreciation And Amortization2.5 M2.1 M1.3 M
Slightly volatile
Selling General Administrative14.7 M25.9 M8.7 M
Slightly volatile
Other Operating Expenses67.2 M96.7 M39 M
Slightly volatile
Research Development52.5 M70.8 M30.3 M
Slightly volatile
Total Operating Expenses67.2 M96.7 M39 M
Slightly volatile
Reconciled Depreciation1.1 M2.1 M724.4 K
Slightly volatile
Cost Of Revenue1.6 M1.7 M19.6 M
Slightly volatile

Bolt Biotherapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation5.4 M10.6 M2.9 M
Slightly volatile
Begin Period Cash Flow18.4 M12.4 M10.6 M
Slightly volatile
Other Cashflows From Financing Activities52.8 M81.7 M35.9 M
Slightly volatile
Depreciation1.1 M2.1 M725.1 K
Slightly volatile
Capital Expenditures225.1 K236.9 K708.7 K
Slightly volatile
Issuance Of Capital Stock317.9 K334.6 K35.9 M
Pretty Stable
Total Cash From Financing Activities276.4 K290.9 K35.8 M
Pretty Stable
End Period Cash Flow14.5 M11.3 M15.2 M
Very volatile
Change To Netincome23.9 M22.8 M7.8 M
Slightly volatile
Change To Liabilities662.1 K696.9 K2.7 M
Pretty Stable
Sale Purchase Of Stock10.9 M12.3 M13.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.876.183.6 K
Slightly volatile
Stock Based Compensation To Revenue1.281.352.6246
Very volatile
Capex To Depreciation0.120.131.1869
Very volatile
EV To Sales7.187.563.5 K
Slightly volatile
Payables Turnover0.690.732.822
Pretty Stable
Sales General And Administrative To Revenue3.133.2919.2567
Slightly volatile
Research And Ddevelopement To Revenue8.548.9992.6408
Slightly volatile
Capex To Revenue0.02860.03012.5019
Pretty Stable
Cash Per Share2.042.431.9577
Slightly volatile
Days Payables Outstanding426666753
Slightly volatile
Income Quality0.660.90.8326
Pretty Stable
Current Ratio4.44.655.1887
Very volatile
Capex Per Share0.0060.00630.0321
Very volatile
Revenue Per Share0.20.190.0533
Slightly volatile
Interest Debt Per Share0.320.480.2012
Slightly volatile
Debt To Assets0.10.110.0613
Slightly volatile
Days Of Payables Outstanding426666753
Slightly volatile
Ebt Per Ebit1.131.041.019
Slightly volatile
Long Term Debt To Capitalization0.50.570.6167
Slightly volatile
Quick Ratio4.424.655.195
Very volatile
Net Income Per E B T1.161.121.02
Slightly volatile
Cash Ratio0.580.613.2786
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.151.0439
Slightly volatile
Fixed Asset Turnover0.310.290.0856
Slightly volatile
Debt Ratio0.10.110.0613
Slightly volatile
Price Sales Ratio5.876.183.6 K
Slightly volatile
Asset Turnover0.04660.04440.0137
Slightly volatile

Bolt Biotherapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap46.3 M48.7 M336.8 M
Pretty Stable
Enterprise Value56.5 M59.5 M330.5 M
Pretty Stable

Bolt Fundamental Market Drivers

Cash And Short Term Investments102.2 M

Bolt Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Bolt Biotherapeutics Financial Statements

Bolt Biotherapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Bolt Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Bolt Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Bolt Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.5 M2 M
Total Revenue9.1 M9.5 M
Cost Of Revenue1.7 M1.6 M
Stock Based Compensation To Revenue 1.35  1.28 
Sales General And Administrative To Revenue 3.29  3.13 
Research And Ddevelopement To Revenue 8.99  8.54 
Capex To Revenue 0.03  0.03 
Revenue Per Share 0.19  0.20 
Ebit Per Revenue(8.71)(9.14)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Bolt Stock Analysis

When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY